The order includes both the portable Nevisense Go pen devices and the necessary electrodes to support the testing volume. Deliveries are scheduled to commence in the fourth quarter of 2026. This financial commitment follows the 2025 licensing agreement between the two firms, which centers on applying AI-driven electrical impedance spectroscopy to predict relapses in patients suffering from atopic dermatitis.

SciBase CEO Pia Renaudin noted that the pace of patient recruitment in their initial joint study has necessitated this additional support. By scaling up the hardware supply, the companies aim to streamline the transition into the second phase of clinical validation. SciBase, which traces its research roots to the Karolinska Institute, continues to position its Nevisense platform as a primary tool for clinicians managing skin health through early, objective intervention.